NCT06353386 2026-03-13
MK-5684-01A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
Clinical Trials
8 trialsNCT06085729 2026-02-27
Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)
M.D. Anderson Cancer Center
Phase 1/2 Suspended
NCT02522715 2026-02-24
Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer
OHSU Knight Cancer Institute
Phase 1/2 Active not recruiting
NCT05340374 2025-04-06
LuCAB
Peter MacCallum Cancer Centre, Australia
Phase 1/2 Active not recruiting
NCT02202772 2025-02-24
CGC
Columbia University
Phase 1/2 Active not recruiting
NCT01335204 2018-07-13
Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer
Medical University of South Carolina
Phase 1/2 Terminated
NCT01751308 2016-08-12
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Sanofi
Phase 1/2 Completed
NCT01001221 2013-09-11
Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor
Sanofi
Phase 1/2 Terminated